Myriad Genetics Inc (MYGN) — Analysis Summary
Myriad Genetics Inc (MYGN) has a market cap of $374.96M with year-over-year revenue growth of -1.6%. Net margin stands at -44.4%. The stock trades at a P/E ratio of -0.9.
Key Takeaways
- Revenue changed -1.6% year-over-year
- Net margin of -44.4%
- P/E ratio of -0.9
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, MYGN posted revenue growth of -1.6% and trades at a P/E of -0.9.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.